The full results of the prematurely terminated GALILEO trial confirm that oral anticoagulation with rivaroxaban was associated with worse clinical outcomes compared with antiplatelet therapy in patients after successful transcatheter aortic valve replacement (TAVR). However, the GALILEO-4D CT sub-study showed that rivaroxaban prevents some leaflet thickening and leaflet motion, indicative of a specific benefit. Both studies were simultaneously published in the New England Journal of Medicine [1,2].
Prof. George Dangas (Icahn School of Medicine at Mount Sinai, USA) pointed out that although current guidelines recommend dual antiplatelet therapy after TAVR, the evidence base for the optimal treatment strategy for patients who have had TAVR is weak . Earlier observational studies provided some evidence that oral anticoagulati...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« FUEL trial: Udenafil improves some exercise measurements in Fontan Next Article
RENAL-AF trial: Apixaban similar to warfarin »
Table of Contents: AHA 2019
New Approaches to CVD Risk Reduction
Interventional Management for Acute Coronary Syndrome
Results for the Ischemia Trials: To Intervene or Not to Intervene
Controversies in Contemporary Management of Aortic Stenosis
Guidelines: Updates and Controversies
Trials in Electrophysiology and Left Ventricular Function
New Frontiers in Lipid Therapy
Challenges in Heart Failure Management
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.